Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...
The extracellular matrix is a complex network of material such as proteins and polysaccharides that are secreted locally by cells and remain closely associated with them to provide structural, ...
The fully automatic Assistina 3x3 takes over the time-consuming process of preparing e.g. straight and contra-angle handpieces and turbines for sterilization.The instrument preparation with Assistina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results